Regulated information

Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT

Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. 

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version)

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

September 2016 year-to-date sales: €257.5 million a 4.8% organic growth

Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. 

Vetoquinol launches its employer brand

The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer.